A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

March 27, 2027

Study Completion Date

September 27, 2027

Conditions

Pancreatic Cancer

Interventions

BIOLOGICAL

IX001 TCR-T injection

IX001 TCR-T injection will be administered intravenously after lymphodepletion.

DRUG

Fludarabine

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

collaborator

ImmuXell Biotech Ltd.

UNKNOWN

lead

Sun Yat-sen University

OTHER